Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03761849 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 899
- Enrollment target
NCT03761849 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 899 participants.
The verdict
NCT03761849, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 899 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in participants with manifest Huntington's disease (HD)
Interventions
- DRUG Placebo
- DRUG RO7234292
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 899 participants |
| Start Date | 2019-01-23 |
| Est. Completion | 2022-03-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03761849
The ClinicalTrials.gov registry entry for NCT03761849 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 899 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03761849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03761849 about?
NCT03761849 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease". This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in participants with manifest Huntington's disease (HD)
What is the current status of trial NCT03761849?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 899 participants. The study started on 2019-01-23. Estimated completion is 2022-03-24.
What interventions are being tested in trial NCT03761849?
The interventions under investigation include: Placebo (DRUG), RO7234292 (DRUG).
Who is sponsoring clinical trial NCT03761849?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.